Asilbek Dauletbaev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Asilbek Dauletbaev has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Atta Ullah Khan
Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Italy
1 shared publication - Barno Matchanova
Department of national idea and philosophy, Urgench state pedagogical institute, Urgench, Uzbekistan
1 shared publication - Erkin Bilalov
Department of Ophthalmology, Tashkent State Medical University, Tashkent, Uzbekistan
1 shared publication - Gulnoza Qurbonova
Department of Psychology and Medicine, Mamun University, Khiva, Uzbekistan
1 shared publication - Gulnoza Tashtemirova
Department of Public Health and Healthcare Management, Rector, Samarkand State Medical University, Samarkand, Uzbekistan
1 shared publication - Intizor Avazmetova
Department of Biology, Urgench State University, Urgench, Uzbekistan
1 shared publication
Latest Publications
- 3 February 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (7) , 2449-2467
The evolution of cellular-based immunotherapy in the treatment of gastric cancer: an overview of clinical trials
Despite advances in patients’ healthcare, gastric cancer remains a major health concern around the world with a high annual incidence rate and mortality. This highlights the urgent need to develop more effective therapeutic strategies, particularly for patients in advanced stages of the disease. In the recent decade, cellular-based immunotherapy has achieved remarkable successes in various hematologic malignancies and solid tumors. Nonetheless, until now, no cellular-based immunotherapy has been approved for GC patients. This review aims to provide a holistic view of the current state of cellular-based immunotherapy for GC, its existing bottlenecks, and future directions to harness the potential of cellular-based immunotherapy for GC treatment. In this regard, we explore clinical trials of various types of cellular-based immunotherapy, including chimeric antigen receptor (CAR)-engineered cell therapy, T cell receptor (TCR)-engineered T cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, cytokine-induced killer (CIK) cell therapy, and dendritic cell (DC) vaccines. For each type of cellular-based immunotherapy, we discuss existing roadblocks to successful treatment and explore potential solutions that may improve efficacy, including novel targets, combination approaches, and biomarker-driven patient selection.
- 3 February 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (7) , 2449-2467
The evolution of cellular-based immunotherapy in the treatment of gastric cancer: an overview of clinical trials
Despite advances in patients’ healthcare, gastric cancer remains a major health concern around the world with a high annual incidence rate and mortality. This highlights the urgent need to develop more effective therapeutic strategies, particularly for patients in advanced stages of the disease. In the recent decade, cellular-based immunotherapy has achieved remarkable successes in various hematologic malignancies and solid tumors. Nonetheless, until now, no cellular-based immunotherapy has been approved for GC patients. This review aims to provide a holistic view of the current state of cellular-based immunotherapy for GC, its existing bottlenecks, and future directions to harness the potential of cellular-based immunotherapy for GC treatment. In this regard, we explore clinical trials of various types of cellular-based immunotherapy, including chimeric antigen receptor (CAR)-engineered cell therapy, T cell receptor (TCR)-engineered T cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, cytokine-induced killer (CIK) cell therapy, and dendritic cell (DC) vaccines. For each type of cellular-based immunotherapy, we discuss existing roadblocks to successful treatment and explore potential solutions that may improve efficacy, including novel targets, combination approaches, and biomarker-driven patient selection.
- 27 December 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (6) , 2086-2098
Prognostic value of postoperative circulating tumor DNA for recurrence-free survival in resected non-small cell lung cancer: a systematic review and meta-analysis
Background Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for minimal residual disease (MRD) detection in resected non-small cell lung cancer (NSCLC), offering potential for risk stratification and treatment optimization in the postoperative setting. Objective To conduct a systematic review and meta-analysis evaluating the prognostic value of postoperative ctDNA detection for recurrence-free survival and overall survival in patients with surgically resected NSCLC. Methods We systematically searched multiple databases including PubMed, Embase, Web of Science, Scopus, and Cochrane Library, identifying 1,640 initial records. After screening and eligibility assessment, 13 studies encompassing 1,309 patients were included in the quantitative synthesis. Results Immediate postoperative ctDNA detection (4 studies, n = 556) demonstrated a hazard ratio of 6.41 (95% CI: 4.18–9.83, P < 0.00001, I2 = 0%) for recurrence-free survival. MRD assessment (9 studies, n = 1,107) yielded HR = 5.48 (95% CI: 3.71–8.10, P < 0.00001, I2 = 38%). Longitudinal ctDNA monitoring (8 studies, n = 1,102) showed the strongest association with HR = 8.70 (95% CI: 6.03–12.54, P < 0.00001, I2 = 21%). Post-adjuvant chemotherapy ctDNA positivity (3 studies, n = 460) resulted in HR = 2.85 (95% CI: 1.56–5.21, P = 0.0006, I2 = 0%). Overall survival analysis (5 studies) demonstrated HR = 4.47 (95% CI: 2.66–7.52, P < 0.00001, I2 = 0%). Conclusions Postoperative ctDNA detection independently predicts prognosis in resected NSCLC, consistently indicating recurrence risk and guiding adjuvant therapy decisions.
- 27 December 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (6) , 2086-2098
Prognostic value of postoperative circulating tumor DNA for recurrence-free survival in resected non-small cell lung cancer: a systematic review and meta-analysis
Background Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for minimal residual disease (MRD) detection in resected non-small cell lung cancer (NSCLC), offering potential for risk stratification and treatment optimization in the postoperative setting. Objective To conduct a systematic review and meta-analysis evaluating the prognostic value of postoperative ctDNA detection for recurrence-free survival and overall survival in patients with surgically resected NSCLC. Methods We systematically searched multiple databases including PubMed, Embase, Web of Science, Scopus, and Cochrane Library, identifying 1,640 initial records. After screening and eligibility assessment, 13 studies encompassing 1,309 patients were included in the quantitative synthesis. Results Immediate postoperative ctDNA detection (4 studies, n = 556) demonstrated a hazard ratio of 6.41 (95% CI: 4.18–9.83, P < 0.00001, I2 = 0%) for recurrence-free survival. MRD assessment (9 studies, n = 1,107) yielded HR = 5.48 (95% CI: 3.71–8.10, P < 0.00001, I2 = 38%). Longitudinal ctDNA monitoring (8 studies, n = 1,102) showed the strongest association with HR = 8.70 (95% CI: 6.03–12.54, P < 0.00001, I2 = 21%). Post-adjuvant chemotherapy ctDNA positivity (3 studies, n = 460) resulted in HR = 2.85 (95% CI: 1.56–5.21, P = 0.0006, I2 = 0%). Overall survival analysis (5 studies) demonstrated HR = 4.47 (95% CI: 2.66–7.52, P < 0.00001, I2 = 0%). Conclusions Postoperative ctDNA detection independently predicts prognosis in resected NSCLC, consistently indicating recurrence risk and guiding adjuvant therapy decisions.